When the world was racing for COVID-19 vaccines, one question cut to the heart of global equity: would manufacturing power stay locked within a handful of wealthy nations, or would it flow outward? Union Health Minister J. P. Nadda, on Tuesday, October 13, 2026, shared a pointed answer — in the words of Prime Minister Narendra Modi. Quoting PM Modi, Nadda posted: 'भारत ने मानवता को एम्पावर करने वाला रास्ता चुना' ('India chose the path that empowers humanity'). The message underscored that when the pandemic exposed the vast inequity in global vaccine access, India made a deliberate call — to supply doses to more than 100 countries rather than ringfence its manufacturing output for domestic use alone.

Vaccine Maitri and the 'Pharmacy of the World' moment

The backdrop to that decision was India's Vaccine Maitri initiative, launched in 2021, which channelled doses from Indian manufacturers to neighbours and developing nations across Africa, Asia, and beyond. India had long carried the informal title of 'pharmacy of the world' — home to the largest generic drug manufacturing base on the planet and facilities capable of producing a significant share of the world's vaccines. During COVID-19, that capacity became a geopolitical and humanitarian asset in one. The post frames the supply decision not as charity but as empowerment — a conscious choice to treat manufacturing capability as a shared resource rather than a national advantage to be hoarded. PM Modi's quoted words draw a direct line between India's industrial strength and a moral stance on global solidarity.

Why the 100-country figure still resonates

The scale matters. Supplying vaccines across 100-plus countries during a fast-moving pandemic required diplomatic coordination, cold-chain logistics, and regulatory clearances running in parallel — not a simple export decision. For many low- and middle-income countries, doses arriving under Vaccine Maitri represented their first meaningful access to COVID-19 immunisation. That reality is what Nadda's post is anchoring: India's manufacturing might translated directly into lives protected outside its own borders. Health Minister Nadda's decision to amplify the PM's words in October 2026 also signals a continued political emphasis on this legacy as India positions itself in conversations around future pandemic preparedness frameworks and global health governance. India's vaccine story during COVID-19 was not without complexity — domestic supply faced pressure as the second wave hit in 2021, prompting a temporary pause in exports. But the broader arc, as Nadda's post invokes it, is one of a nation that returned to outward supply and made global equity a stated pillar of its health diplomacy. The question now is how that legacy shapes India's commitments in the next round of multilateral pandemic preparedness negotiations.